Skip to main content
TipRanks
Go Ultimate75% OFF

Control Bionics Ltd. (CBL) AI Stock Analysis

3 Followers
AU:CBL

Control Bionics Ltd.

(ASX:CBL)

Select Model
Rating:42Neutral
Price Target:AUD 0.05â–¼(-1.89% Downside)
Action:reiterated
Date:10/29/26

The score is held down primarily by weak financial performance, driven by persistent losses, a negative gross margin in 2026, and ongoing negative operating/free cash flow. Technicals add pressure with the stock trading below key moving averages and a negative MACD. Valuation provides limited support because the negative P/E reflects unprofitable operations and there is no dividend yield data to offset risk.

Positive Factors
Conservative leverageModest leverage limits the immediate burden of interest and debt repayment, giving Control Bionics more financial flexibility than a highly indebted company. This supports resilience while management addresses operating losses, although it does not remove the need to improve profitability and cash generation.
Negative Factors
Declining revenue and persistent lossesRecent revenue deterioration combined with recurring large operating and net losses indicates that the business has not yet established a dependable path to scale economics. Continued weakness could restrict investment capacity and make future growth increasingly dependent on external funding.

Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)

-30%-20%-10%0%10%20%30%40%50%AU:CBL-15.87%EWA+17.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 28.84M
Dividend Yield
―
Average Volume (3M)
500.71K
Price to Earnings (P/E)
-2.7
Beta (1Y)
-0.17
Revenue Growth
-22.43%
EPS Growth
15.02%
Country
Australia
Employees
25
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Control Bionics Ltd. Business Overview & Revenue Model

Company Description

Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the Neuro...

Control Bionics Ltd. Financial Statement Overview

Summary

Overall financial quality is weak. The income statement shows volatile and declining revenue (2026 down ~21%) with persistent large operating/net losses and a concerning shift to negative gross margin in 2026. Cash flow remains consistently negative (operating cash flow and free cash flow negative every year), indicating ongoing cash burn. The main offset is a relatively conservative balance sheet with low leverage, but equity has been declining due to continued losses.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue4.77M4.77M6.14M5.35M5.64M4.50M
Gross Profit-3.92M-4.14M4.11M3.90M3.71M-2.91M
EBITDA-6.86M-7.29M-4.97M-5.01M-5.14M-6.01M
Net Income-7.27M-7.27M-6.11M-5.91M-5.63M-6.11M
Balance Sheet
Total Assets9.05M9.05M8.23M9.03M8.70M13.44M
Cash, Cash Equivalents and Short-Term Investments2.08M2.08M672.66K980.76K935.50K5.21M
Total Debt618.92K618.92K435.40K961.74K128.50K284.82K
Total Liabilities2.73M2.73M2.72M2.76M1.58M1.51M
Stockholders Equity6.31M6.31M5.51M6.27M7.15M11.92M
Cash Flow
Free Cash Flow-5.76M-5.76M-4.57M-5.38M-4.98M-5.75M
Operating Cash Flow-5.75M-5.75M-4.27M-4.91M-4.53M-5.60M
Investing Cash Flow-269.80K-269.80K-744.78K-473.09K-457.54K-147.74K
Financing Cash Flow7.49M7.49M4.63M5.43M706.43K-87.33K

Control Bionics Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.05

Price Trends

50DMA0.06Negative
100DMA0.06Negative
200DMA0.06Negative

Market Momentum

MACD-0.00Negative
RSI37.48Neutral
STOCH35.71Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 37.48 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CBL.

Control Bionics Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:CBL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:COHAU:COH68NeutralAUD 9.90B67.288.01%2.28%-0.90%-62.14%
AU:EYEAU:EYE57NeutralAUD 45.59M-10.53-28.79%―19.13%58.47%
AU:CMPAU:CMP54NeutralAUD 48.94M222.730.93%―18.54%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:EMVAU:EMV50NeutralAUD 132.46M-15.61-46.84%――20.40%
AU:NTIAU:NTI48NeutralAUD 32.32M-4.54-201.54%―-100.00%50.49%
AU:CBLAU:CBL42NeutralAUD 28.84M-2.68-103.48%―-22.43%15.02%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%50%AU:CBLAU:EYEAU:COHAU:CMPAU:NTIAU:EMVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:CBL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:CBLControl Bionics Ltd.0.05-0.01-13.11%
AU:EYENova Eye Medical Ltd0.160.0323.08%
AU:COHCochlear Limited151.37-115.52-43.28%
AU:CMPCompumedics Limited0.24-0.10-28.99%
AU:NTINeurotech International Ltd.0.020.0025.00%
AU:EMVEMvision Medical Devices Ltd.1.43-0.38-20.83%

Control Bionics Ltd. Corporate Events

Control Bionics to Present at Bell Potter Healthcare Conference

Nov 11, 2026

Control Bionics Limited is a neurotechnology company commercialising non-invasive neural-signal technology across performance, rehabilitation, research and data, and assistive communication. Its platform captures physiological signals, including musc...

Control Bionics Director Boosts Stake with On-Market Share Purchase

Oct 29, 2026

Control Bionics Limited has disclosed a change in director Stephen Rix’s shareholding, reporting an on-market purchase of 1,000,000 ordinary shares. The acquisition, made through Windward Capital Pty Limited where Rix is a director and shareholder, i...

Control Bionics builds cash runway as new assistive devices gain traction

Oct 28, 2026

Control Bionics reported unaudited revenue growth in each month of the September quarter, ahead of the June period, with cash receipts of $1.0 million and net operating cash outflows of $2.8 million driven partly by short-term incentives and one-off...

Control Bionics launches fee-free sale facility for small shareholders

Oct 28, 2026

Control Bionics Limited has introduced a share sale facility for investors holding parcels of its shares worth less than A$500, allowing these smaller shareholders to sell their holdings without using a broker or paying transaction fees. The company...

Control Bionics Issues Over 1 Million New Shares While Confirming Regulatory Compliance

Oct 19, 2026

Control Bionics Limited has issued 1,044,087 fully paid ordinary shares on 19 October 2026, expanding its share capital without providing a disclosure document under the relevant fundraising provisions of the Corporations Act. The company confirmed i...

Control Bionics Director Boosts Stake Through Equity-Based Fees

Oct 19, 2026

Control Bionics director Stephen Rix has increased his combined direct and indirect holding in the company through the issue of 1,044,087 ordinary shares. The shares, valued at $62,356, were issued in lieu of directors’ fees following approval at the...

Control Bionics Wins Strong Shareholder Backing at 2026 AGM

Oct 13, 2026

Control Bionics Limited held its Annual General Meeting on 13 October 2026, where shareholders voted on a series of governance and capital-related resolutions. The company, a medtech player specialising in assistive communication technologies for peo...

Control Bionics Moves From Foundations to Commercial Conversion

Oct 12, 2026

Control Bionics Ltd., listed on the ASX as CBL, operates in the assistive technology and medical device industry, offering neuro-based communication and control solutions to support people with severe physical disabilities. Its products and systems a...

Control Bionics Options Expire, Trimming Potential Dilution

Oct 11, 2026

Control Bionics Limited has notified the market that a tranche of listed options, trading under the ASX code CBLAU and carrying an exercise price of $0.10, has expired unexercised. The options, which were scheduled to expire on October 10, 2026, ceas...

Control Bionics Wins CE Mark for NeuroStrip, Expanding Access Across Europe

Oct 4, 2026

Control Bionics has secured CE marking for its NeuroStrip wearable sEMG device as a Class I medical device under the EU Medical Device Regulation, following its registration in the European Database on Medical Devices. This certification allows the c...

Control Bionics flags ASX Listing Rule breach over Phoenix loan facility

Sep 28, 2026

Control Bionics has disclosed that it breached ASX Listing Rule 10.1 in relation to a $400,000 loan facility it accepted from substantial shareholder Phoenix Development Fund, which was to be secured over its anticipated FY26 R&D tax incentive refund...

Control Bionics Sets October Date for 2026 AGM and Moves to Digital Meeting Materials

Sep 11, 2026

Control Bionics Limited has called its 2026 Annual General Meeting for 13 October in Sydney, inviting shareholders to attend or participate via proxy voting. The company is shifting to electronic distribution of meeting materials, with notices and ke...

Control Bionics Sets 2026 AGM to Vote on Board, Incentive Plans and Extra Capital Capacity

Sep 11, 2026

Control Bionics Limited has convened its 2026 Annual General Meeting for 13 October in Sydney, setting out standard governance items including consideration of its 2026 financial report and adoption of the remuneration report. Shareholders will also...

Control Bionics Issues 1.6 Million Unquoted XV Options

Sep 7, 2026

Control Bionics Limited has notified the market of the issue of 1,600,000 unquoted XV Options, effective 7 September 2026, under a new class of securities to be confirmed on the ASX. The issuance of these options suggests the company is using equity-...

Control Bionics Director Stephen Rix Increases Shareholding

Sep 1, 2026

Control Bionics director Stephen Rix has increased his holding in the company through an on-market purchase of additional ordinary shares. The transaction, conducted on 1 September 2026, lifted his total direct and indirect shareholding to 8,959,913...

Control Bionics sets cautious tone as it shifts from repositioning to growth

Aug 27, 2026

Control Bionics Ltd., listed on the ASX under ticker CBL, is a developer of assistive communication and neuro-based interface technologies designed for people with severe physical disabilities. Its solutions are used across healthcare and disability...

Control Bionics Files Updated ASX Corporate Governance Statement

Aug 27, 2026

Control Bionics Limited has lodged its latest corporate governance statement for the year ended 30 June 2026, confirming it complies with ASX Listing Rule requirements by hosting the statement on its website and filing the accompanying Appendix 4G. T...

Control Bionics Sets Growth Agenda Around Unified Assistive Tech Platform

Aug 27, 2026

Control Bionics Limited’s latest annual report outlines a unified platform strategy supporting three commercial pillars in the assistive technology space. The company continues to focus on products that enable communication and device control for peo...

Control Bionics Posts Wider Loss as It Takes Full Control of U.S. Neurotech Unit

Aug 27, 2026

Control Bionics Limited reported a 22.4% decline in revenues from ordinary activities to $4.77 million for the year ended 30 June 2026, alongside an 18.9% increase in loss after tax to $7.27 million, as the group continues to invest in its assistive...

Control Bionics to unveil FY26 results with investor webcast

Aug 27, 2026

Control Bionics Limited will release its financial results for the full year ended 30 June 2026 on Friday 28 August 2026, highlighting its performance as a neurotechnology specialist in non‑invasive neural‑signal platforms. The company has scheduled...

Control Bionics Wins Key U.S. Medicare Code for UnoTouch Omni Speech Devices

Aug 26, 2026

Control Bionics has secured U.S. Medicare PDAC coding verification for two UnoTouch Omni speech generating devices, clearing the final regulatory hurdle for market access. The devices have been assigned HCPCS code E2510, the highest-value Medicare ba...

Control Bionics wins UK approval for NeuroStrip, advancing international expansion

Aug 25, 2026

Control Bionics Limited has secured registration from the UK Medicines and Healthcare products Regulatory Agency for its NeuroStrip wearable surface electromyography device, clearing the key regulatory barrier to commercial supply across Great Britai...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026